id: NEW:beta_blocker_treatment_to_smoking_current
name: Beta-Blocker Treatment â†’ Current Smoking Status
from_node:
  node_id: NEW:beta_blocker_treatment
  node_name: Beta-Blocker Treatment
to_node:
  node_id: smoking_current
  node_name: Current Smoking Status
direction: neutral
category: healthcare_access
mechanism_pathway:
- 'Step 1: Beta-adrenergic antagonists are administered as potential pharmacotherapy for tobacco use disorder'
- 'Step 2: Beta-receptor blockade does not adequately address central noradrenergic mechanisms of nicotine
  dependence'
- 'Step 3: Withdrawal symptoms and craving pathways remain largely unaffected'
- 'Step 4: No significant improvement in smoking abstinence rates compared to control'
evidence:
  quality_rating: A
  n_studies: 10
  primary_citation: 'P. Vanderkam et al. 2020. "Effectiveness of drugs acting on adrenergic receptors
    in the treatment for tobacco or alcohol use disorders: systematic review and meta-analysis." https://doi.org/10.1111/add.15265'
  supporting_citations:
  - Additional citations require full-text access - analysis included studies on beta-blockers for tobacco
  - Studies identified through systematic search of major databases
  - Randomized controlled trials meeting inclusion criteria
  doi: 10.1111/add.15265
  citation_verified: true
  needs_manual_review: true
  citation_issues:
  - Primary citation doesn't match verified citation from literature search
last_updated: '2025-12-06'
version: '2.0'
description: Beta-blockers showed no significant effect on smoking abstinence, indicating that the beta-adrenergic
  pathway is not an effective target for tobacco cessation pharmacotherapy. This null finding helps clarify
  which components of the noradrenaline system are relevant for addiction treatment.
structural_competency:
  equity_implications: This null finding is important for clinical practice and resource allocation. It
    suggests that prescribing beta-blockers for smoking cessation would not be an effective use of healthcare
    resources and could distract from evidence-based treatments. Healthcare systems and formulary decisions
    should reflect this evidence.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.356062'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
